Company / Operating Income
Vivos Therapeutics, Inc. Operating Income History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$11.2M
FY2025
5-year range
-$25.0M / -$11.2M
FY2021-FY2025
Trend
+35.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -$25M to -$11M over the past 2 years.
Based on SEC 10-K filings.
-$11M in FY2025.
Improved from -$25M to -$11M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income increased 35.4% year-over-year.
- Peak operating income was recorded in FY2020.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$11.2M | +35.4% |
| FY2024 | -$17.3M | +30.9% |
| FY2023 | -$25.0M | -22.8% |
| FY2022 | -$20.4M | -69.3% |
| FY2021 | -$12.0M | -13.8% |
| FY2020 | -$10.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026